Triumeq thumbs up

Home»Health & treatment»HIV treatment»Triumeq thumbs up
02 Jul 2014

ViiV Healthcare announced on 27 June that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has issued a positive opinion recommending marketing authorisation for Triumeq.

Triumeq is a fixed-dose combination containing dolutegravir, abacavir and lamivudine.  All three drugs are singularly approved for the treatment of HIV in Australia, the US and Europe and other parts of the world; abacavir and lamivudine are also available in the duel-dose combination, Kivexa.  Many people are taking these individual drugs together, and the availability of a coformulation of all three into a single pill would make taking this combination easier and less expensive.

The approval and availability of Triumeq would offer people living with HIV the first ‘0ne pill once a day’ single tablet without food requirements or restrictions.

 "Today's positive opinion takes us a step closer to bringing physicians and people living with HIV a dolutegravir-based regimen that can be taken once-daily as a single-tablet," said Dr John Pottage, Chief Scientific and Medical Officer, ViiV Healthcare. "This opinion supports the potential of dolutegravir-based regimens, as well as the importance of our ongoing research into additional single-tablet treatment options.”

 An application for the licensing of Triumeq is with the Therapeutic Goods Administration (the TGA is Australia's regulatory agency for medical drugs and devices).